Physician profile
David Suhrbier
NPI 1629070651
$12,262.24
in general payments reported to CMS, 2019-2025
19 companies · $58.25 in 2025
The $58.25 reported for 2025 was less than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,078 · 2020: $3,233 · 2021: $350 · 2022: $44.77 · 2023: $365 · 2024: $133 · 2025: $58.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $11,199.54 | 2019-2021 | |
| Neurelis, INC. | $149.97 | 2020-2024 | Valtoco |
| Abbvie INC. | $125.72 | 2023-2025 | Botox |
| Ucb, INC. | $119.61 | 2019-2021 | |
| Harmony Biosciences LLC | $112.49 | 2020 | |
| Sunovion Pharmaceuticals INC. | $89.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $76.53 | 2022-2024 | Dupixent |
| Jazz Pharmaceuticals INC. | $69.96 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $62.31 | 2023-2024 | Dysport |
| Supernus Pharmaceuticals, INC. | $50.82 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $41.59 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $27.63 | 2023 | Eprontia |
| Baxter Healthcare | $26.20 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Amneal Pharmaceuticals LLC | $22.98 | 2023 | Lyvispah |
| Greenwich Biosciences, INC. | $22.08 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $20.05 | 2025 | Lumryz |
| Acadia Pharmaceuticals INC | $16.30 | 2023 | Daybue |
| Biomarin Pharmaceutical INC. | $14.79 | 2024 | Brineura |
| Ptc Therapeutics, INC. | $14.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Suhrbier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.